Cell Expansion in Regenerative Medicine: What Lab Processing Involves

Two clinics describe what sounds like the same procedure. The first calls it “cell concentration.” The second calls it “cell expansion.” A patient who scrolls between two consultation websites at 10:18 PM, the FDA regulatory page open in a third tab, encounters the words within the same fifteen minutes and assumes they describe the same lab work. They do not. The first describes a centrifuge run that takes thirty minutes between harvest and reinjection. The second describes a multi-week growing-out of cells in a culture facility before reinjection. The same patient. The same target joint. The same harvest. Two products on two regulatory pathways.

The patient researching cell-based therapy in 2026 needs to know which one a given clinic is offering, why the FDA treats them differently, and what documentation a quality clinic produces at each step.

What Lab Processing Includes Beyond Cell Concentration

A standard same-day autologous procedure runs through a short sequence in the clinic. The harvest, usually bone marrow drawn from the iliac crest or adipose tissue from the abdomen or flank, arrives at a clinic-side bench. A centrifuge separates the cellular fraction from the rest of the tissue. The concentrated fraction is drawn into a syringe. The injection follows the same day, often within an hour of the harvest. The lab work is mechanical, fast, and minimal. The cells are not grown. They are not selected by surface marker. They are not changed in any way other than concentrated and washed.

A more involved processing chain looks different. The harvest still happens in the clinic. The cells then travel to a culture laboratory, sometimes on-site at the same clinic, often at a separate facility. There, technicians plate the cells in culture flasks or bioreactors, feed them with media containing growth factors, and let them divide over several days to several weeks. Some labs select for specific cell populations using surface marker sorting before or after the culture step. Some labs run quality assays at intervals through the culture period. The cells that come back to the patient are not the same cells that left the harvest site. They have grown. They have been selected, washed, and reformulated. The sequence may take days. It may take weeks. The reinjection is a separate appointment, not the same day.

The two processing chains produce two different products. They sit on two different regulatory pathways. They carry two different cost structures. They demand two different conversations with the patient.

How Cell Concentration and Cell Expansion Differ in the Lab

Cell concentration relies on physics. The centrifuge spins, and components of different densities separate. Bone marrow concentrate, processed this way, contains the cellular fraction of the marrow harvest, including stem cells, progenitor cells, platelets, and a number of supporting cell types. The product is what came out of the patient, minus the plasma and other less-cellular components, plus whatever processing aids were used in the wash.

Cell expansion relies on biology. The same harvest, if culture-expanded, becomes a population of cells that have divided many times in the culture flask. Mesenchymal stromal cell precursors in bone marrow are present in low percentages and are typically expanded through several culture passages to reach therapeutic doses. The published literature, accessible through NIH PubMed Central, documents that two to three passages are common in clinical trial settings, and that proliferation and differentiation potential tend to decrease at higher passage numbers. Recommended starting points sit at passage two or earlier. The therapeutic dose target may be reached in roughly two to nine weeks, depending on the protocol and the patient’s starting cell yield.

Two practical points worth carrying into a consultation:

The product the patient receives after expansion is not the same population that left their body. The cells have divided, sometimes adapted to plastic, and may have shifted in surface marker expression and functional properties.
The longer the expansion, the more risk of genomic drift, loss of differentiation potential, or contamination, and the more important the lab’s quality control becomes.

The ISCT minimal criteria for mesenchymal stromal cells, in their long-standing position statement and the May 2025 update, define the surface marker profile and functional assays that an expanded MSC product should meet to be called what the marketing says it is.

FDA Regulatory Categories: 361 vs. 351 Products Explained

The FDA framework for human cells, tissues, and cellular and tissue-based products turns on the criterion of minimal manipulation. A product is minimally manipulated, in the FDA’s regulatory definition, when processing does not alter the relevant biological characteristics of the cells. Centrifugation alone, in most cases, qualifies as minimal manipulation. Culture expansion does not. The FDA’s regulatory considerations document on minimal manipulation and homologous use, current guidance for the field, treats culture expansion as more than minimal manipulation in the standard interpretation.

The category determines the regulatory pathway:

Category	Common processing	Pathway	Approval requirement
Minimally manipulated, homologous use	Centrifugation, filtration, washing	Section 361	Tissue establishment registration, current good tissue practice
More than minimally manipulated	Culture expansion, surface-marker selection, genetic modification	Section 351	Investigational new drug application, biologics license application

A clinic offering a culture-expanded product without an investigational new drug authorization or a biologics license is offering a product that the FDA framework places under Section 351 without the corresponding approval. The framework page makes the categorization clear. The clinic’s responsibility is to operate within it. The patient’s responsibility, when the consultation does not surface the question, is to ask which pathway applies and what number is on the approval letter.

Which Quality Control Steps Patients Should See Documented

A culture-expanded product, properly handled, generates documentation at multiple steps. A bench-side concentration run generates less, but it still generates some. Across both, the patient evaluating clinic capability has a short list of items worth seeing in writing:

Cell count, expressed as total cells delivered or per-milliliter concentration in the final product
Cell viability, expressed as the percentage of live cells at the time of preparation or shipment
Cell type identity, where applicable, reported through surface marker profiles for MSCs or comparable identity assays for other cell types
Sterility testing results, particularly for products that spend any time outside the patient’s body in a culture environment
Potency or functional assay results, where the product’s intended action depends on a measurable biological function
For expanded products, passage number at the time of injection

For minimally manipulated bench-side concentrate, cell count and viability are the most consistent documentation a quality clinic produces. For culture-expanded products, the full set above is what the ISCT framework and the FDA quality expectations together describe. A patient who asks for these documents and receives a clear answer, even one that says “we do not run that assay because the product type does not require it,” is in a different conversation from a patient who receives a vague answer or none.

Why Some Clinics Send Samples Out and Others Process On-Site

A clinic-side bench centrifuge, operated by trained staff, suffices for minimally manipulated autologous procedures. The setup is small, the cost is contained, and the same-day procedure structure is what most autologous orthopedic clinics deliver. Many of them keep this work on-site for that reason.

A culture facility looks different. It needs cleanroom-grade environments, biosafety cabinets, incubators, validated procedures, and trained staff who handle multiple samples in parallel. The facility’s regulatory standing has to align with whatever pathway the product follows. Some clinics operate their own facility on-site. Many partner with a contract cell-processing facility that handles the lab work and ships the product back. Both arrangements are workable when the facility is qualified and the chain of custody is documented.

The patient questions that follow from the on-site versus off-site arrangement are short and useful:

Which entity processes the cells, and what is the facility’s name?
What FDA category does the product fall under, and is the facility registered or approved accordingly?
For shipped products, what is the cold-chain protocol and the time from harvest to reinjection?
For on-site processing, who is the qualified person responsible for processing decisions?

When a clinic answers these questions in operational language, the consultation is doing its job. When the answers slide into general reassurance without operational detail, the patient has identified one of the gaps that good lab processing tends to close in writing.

Where Lab Processing Claims Tend to Fall Apart

Lab processing claims, in patient-facing materials, tend to use language that sounds technically substantive but lands on the marketing side of the line. A short scan helps the patient sort one from the other:

Claims about cell potency that do not specify which assay produced the number or which lot the number describes
Claims about cell viability without a sample-size context or a time-of-measurement context
Claims about FDA registration that conflate tissue establishment registration with FDA approval, when the two mean different regulatory things
Claims about “proprietary processing” that do not explain what the proprietary step is, and whether it shifts the product into more-than-minimally-manipulated territory
Claims that an autologous product is somehow exempt from FDA standards, when in fact autologous products are subject to the same minimal manipulation and homologous use criteria as any other HCT/P
Claims that imply allogeneic donor products are uniformly safer or more potent than autologous, when the published literature consistently demonstrates neither

When a clinic’s processing claims read clearly against the FDA framework, the ISCT minimal criteria, and the published large-scale expansion literature, the consultation is operating in the same vocabulary the regulators use. When the claims slide past those references, the open research question becomes which framework the clinic is operating under, and whether that framework matches what was actually said in the consultation.

By 11:14 PM the FDA regulatory page is still open in the patient’s third tab. The two clinic websites in the first and second tabs read differently now. One uses “cell concentration.” The other uses “cell expansion.” The patient knows which Section number applies to each, what documentation each should produce, and which questions get the consultation back to operational language. What can be matched is what the clinic claims against what the FDA framework, the ISCT criteria, and the published research describe. Where those line up, the consultation is doing its work. Where they diverge, the consultation is not yet finished.

Important note on cell-source decisions: No cell-source or processing approach removes the regulatory framework risk, and FDA distinctions between 351 and 361 products affect what clinics may legally offer. The realistic question is what documentation the patient asks for and what specific practices verify a clinic operates within current FDA guidance.

Sources: